Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending December 13, 2005. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding Ordinary Shares of the registrant.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of specific share transactions rather than a financial performance report.
Material Changes
The filing details a change in the number of Ordinary Share ADRs held by the GlaxoSmithKline US Retirement Savings Plan ("the Plan").
- Date of Movement: December 8, 2005
- Previous Holding: 18,474,542 ADRs
- New Holding: 18,453,028 ADRs
- Average Price: $51.04
- Reason: A movement in the fund.
Guidance, Outlook, and Risks
The filing does not contain management commentary, financial guidance, outlook, or risk factors. It notes that the Plan is a discretionary fund for employees and former employees. Two directors, Dr. J P Garnier and Dr. T Yamada, are potentially interested in the shares held in the fund in the same manner as other employees. The transaction was notified in accordance with Disclosure Rule 3.1.4 R (1) (b).
Key Facts for Investor Verification
- Verify the impact of the fund movement on the total share count held by the US Retirement Savings Plan.
- Confirm the potential interest of Directors Dr. J P Garnier and Dr. T Yamada in the fund's holdings.
- Note that this filing does not reflect operational or financial performance metrics for the period.